Rekombinanter SARS-CoV-2 Spike S1 Antikörper (RBD)

Produktnummer ABIN6952546

Produktdetails anti-SARS-CoV-2 Spike S1 Antikörper

Highlights:

• Recombinant human neutralizing antibody (hNAb) against SARS-CoV-2.
• Binds SARS-CoV-2 S proteins of lineages B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), B.1.617.2 (delta), B.1.1.529 (omicron), B.1.429 (epsilon), B.1.525 (eta), and B.1.617.1 (kappa).
• Frequently used as reference in S-protein ELISAs and neutralization assays.
• Synergizes with other hNAbs: binds a highly conserved epitope, not interefering with the S-protein's ACE2 RBD.

Target: SARS-CoV-2 Spike S1

Antikörpertyp: Recombinant Antibody

Bindungsspezifität: RBD

Reaktivität: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV), SARS CoV-2 Alpha, SARS CoV-2 Beta, SARS CoV-2 Epsilon, SARS CoV-2 Gamma, SARS CoV-2 Eta, SARS CoV-2 Kappa, SARS CoV-2 Delta, SARS CoV-2 Omicron

Wirt: Human

Klonalität: Monoklonal

Konjugat: Dieser SARS-CoV-2 Spike S1 Antikörper ist unkonjugiert

Applikation: ELISA, Immunofluorescence (IF), Crystallization (Crys), Surface Plasmon Resonance (SPR), Multiplex Immunohistochemistry (mIHC)

Verwendungszweck: Recombinant monoclonal antibody CR3022 to SARS-CoV S Glycoprotein.

Spezifität:

The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).

Kreuzreaktivität (Details): The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).

Produktmerkmale:

OriginalSpeciesName: Human

OriginalFormat: IgG1

Aufreinigung: Protein A affinity purified

Immunogen: The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Klon: CR3022

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: This antibody (CR3022) binds to both SARS-CoV and SARS-CoV-2 with high affinity. The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1 is available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Independent Validation (mIHC)

Validierung #104441 (Multiplex Immunohistochemistry)

by: Akoya Biosciences

No.: #104441

Datum: 13.09.2022

Antigen: SARS-CoV-2 Spike S1

Chargennummer: T2023B03

Validierte Anwendung: Multiplex Immunohistochemistry

Positivkontrolle:

FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2

Negativkontrolle:

SARS-CoV-2-negative placenta patient sample

Bewertung:

Passed. The anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 produced staining in FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2.

Validierungsbilder

Immunofluorescence of SARS-CoV-2 infection in FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2. Anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 is visualized with PhenoCycler reporters in green and DAPI-stained chromatin in blue.

Immunofluorescence of SARS-CoV-2 infection in FFPE cell pellets from in vitro cultured human lung cells infected with SARS-CoV-2. Costaining with anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 (green) and anti-SARS-CoV-2 Nucleocapsid Protein antibody ABIN6952544 (red).

Protokoll

Primärantikörper: ABIN6952546

Full Protocol:

• Protocol details are described in the Akoya Biosciences CODEX® User Manual (see https://www.akoyabio.com/wp-content/uploads/2021/01/CODEX-User-Manual.pdf).
• Tissue preparation as outlined in the Akoya Biosciences CODEX® User Manual FFPE tissue protocol.
• Conjugation of the anti-SARS-CoV-2 Spike S1 antibody RBD antibody ABIN6952546 as described in Chapter 4 of the Akoya Biosciences CODEX® User Manual.
• Autofluorescence quenching according to the Autofluorescence Quenching Protocol for CODEX® (see https://www.akoyabio.com/wp-content/uploads/2020/07/Customer-Demonstrated-Protocol-Autofluorescence-Quenching-Mar2020.pdf).

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Referenzen für anti-SARS-CoV-2 Spike S1 Antikörper (ABIN6952546)

Kannenberg, Trawinski, Henschler, Buhmann, Hönemann, Jassoy: "Antibody course and memory B-cell response in the first year after SARS-CoV-2 infection." in: The Journal of infectious diseases, (2022) (PubMed).

Jacobsen, Fabricius, Class, Topfstedt, Lorenzetti, Janowska, Schmidt, Staniek, Zernickel, Stamminger, Dietz, Zellmer, Hecht, Rauch, Blum, Ludwig, Jahrsdörfer, Schrezenmeier, Heeg, Mayer, Seidel, Groß et al.: "High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection. ..." in: Nature communications, Vol. 13, Issue 1, pp. 7315, (2022) (PubMed).

Hennrich, Sawatsky, Santos-Mandujano, Banda, Oberhuber, Schopf, Pfaffinger, Wittwer, Riedel, Pfaller, Conzelmann: "Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization." in: PLoS pathogens, Vol. 17, Issue 4, pp. e1009064, (2021) (PubMed).

Tian, Li, Huang, Xia, Lu, Shi, Lu, Jiang, Yang, Wu, Ying: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." in: Emerging microbes & infections, Vol. 9, Issue 1, pp. 382-385, (2020) (PubMed).

Stadlbauer, Amanat, Chromikova, Jiang, Strohmeier, Arunkumar, Tan, Bhavsar, Capuano, Kirkpatrick, Meade, Brito, Teo, McMahon, Simon, Krammer: "SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup." in: Current protocols in microbiology, Vol. 57, Issue 1, pp. e100, (2020) (PubMed).

Yuan, Wu, Zhu, Lee, So, Lv, Mok, Wilson: "A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV." in: Science (New York, N.Y.), (2020) (PubMed).

Pinto, Park, Beltramello, Walls, Tortorici, Bianchi, Jaconi, Culap, Zatta, De Marco, Peter, Guarino, Spreafico, Cameroni, Case, Chen, Havenar-Daughton, Snell, Telenti, Virgin, Lanzavecchia, Diamond et al.: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody." in: Nature, (2020) (PubMed).

ter Meulen, van den Brink, Poon, Marissen, Leung, Cox, Cheung, Bakker, Bogaards, van Deventer, Preiser, Doerr, Chow, de Kruif, Peiris, Goudsmit: "Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants." in: PLoS medicine, Vol. 3, Issue 7, pp. e237, (2007) (PubMed).

Details zu SARS-CoV-2 Spike S1

Target: SARS-CoV-2 Spike S1

Abstract: SARS-CoV-2 Spike S1 Produkte

Synonyme: E2 antikoerper, Surface Glycoprotein antikoerper, S antikoerper

Substanzklasse: Viral Protein

Hintergrund: Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV

UniProt: P59594